A clinical study of the efficacy of a single session of individual exercise for depressive patients, assessed by the change in saliva free cortisol level by unknown
Ida et al. BioPsychoSocial Medicine 2013, 7:18
http://www.bpsmedicine.com/content/7/1/18RESEARCH Open AccessA clinical study of the efficacy of a single session
of individual exercise for depressive patients,
assessed by the change in saliva free cortisol
level
Megumi Ida1*, Itsurou Ida2, Naoki Wada3, Makoto Sohmiya1, Masayuki Tazawa3 and Kenji Shirakura1Abstract
Background: The efficacy of physical exercise as an augmentation to pharmacotherapy with antidepressants for
depressive patients has been documented. However, to clarify the effectiveness of exercise in the treatment of
depression, it is necessary to distinguish the effect of the exercise itself from the effect of group dynamics.
Furthermore, an objective measurement for estimation of the effect is needed. Previous reports adopted a series
of group exercises as the exercise intervention and mainly psychometric instruments for the measurement of
effectiveness. Therefore, this clinical study was done to examine the effectiveness of a single session of individual
exercise on depressive symptoms by assessing the change in saliva free cortisol level, which reflects
hypothalamic-pituitary-adrenocortical axis function that is disturbed in depressive patients.
Method: Eighteen medicated patients, who met the DSM-IV-TR criteria for major depressive disorder, were
examined for the change in saliva free cortisol levels and the change in subjective depressive symptoms before and
after pedaling a bicycle ergometer for fifteen minutes. Within a month after the exercise session, participants
conducted a non-exercise control session, which was sitting quietly at the same time of day as the exercise session.
Results: Depressed patients who participated in this study were in remission or in mild depressive state. However,
they suffered chronic depression and had disturbed quality of life. The saliva free cortisol level and subjective
depressive symptoms significantly decreased after the exercise session. Moreover, the changes in these variables
were significantly, positively correlated. On the other hand, although the subjective depressive symptoms improved
in the control session, the saliva free cortisol level did not change.
Conclusion: For the first time in depressive patients, we were able to show a decrease in the saliva free cortisol
level due to physical exercise, accompanied by the improvement of subjective depressive symptoms. This identified
a possible influence of exercise on the hypothalamic-pituitary-adrenal axis in depression.
These results suggest the utility of assessing the effect of physical exercise by saliva free cortisol level in depressive
patients who suffer from bio-psycho-social disability.
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In this clinical study, we aimed to clarify the efficacy of
physical exercise on depressive symptoms by adopting a
single session of individual exercise as the exercise for-
mat and by assessing the change in the saliva free corti-
sol level as an evaluation tool.
According to the International Classification of Dis-
eases 10th Revision (ICD-10) [1], a person with depres-
sion suffers from a depressed mood, loss of interest and
enjoyment, reduced energy leading to increased fatigabil-
ity, and diminished activity. Depression often involves
somatic symptoms such as disturbed sleep or appetite
and weight loss, and it disturbs not only psychological
but physical and social aspects of a person’s life. In
addition, depression is essentially an episodic recurring
disorder and often becomes chronic [2].
The first–line of treatment for depression is pharma-
cotherapy with antidepressants. However, the remission
rate with selective serotonin reuptake inhibitors, which
are currently the first-line medication, is only at most
60% [3]. Even after continuation and maintenance use of
antidepressants after remission became common, the
high rate of recurrence and chronicity of depressive epi-
sodes has not been resolved [4,5].
In addition, recent studies about psychosocial disabil-
ity in depression disclosed that the disability, which is
directly correlated with the severity of depression,
chronically persisted, even in inter-episode or in remis-
sion periods [6,7]. Moreover, while depression affects in-
dividuals at any life stage, the incidence is the highest in
middle age when a person must play important social
and family roles [2]. In the Global Burden of Disease
(GBD) Study, which is a large-scale survey of the health
burden of all diseases that takes chronicity as well as
mortality of diseases into consideration, in 2004 unipolar
depressive disorders were ranked the third cause of the
burden of all diseases, and they are estimated to be the
first cause by 2030 for all ages [8].
An effective augmentative approach for use in addition
to continuation and maintenance medication is strongly
required for depressive patients.
The contribution of physical exercise to mental health
has been reported since the 1980s. Morgan claimed that
prevention of a sedentary lifestyle, which is common in
modern life, was important for maintaining mental as
well as physical health [9]. Additionally, it has been
shown that physical activity can potentially prevent de-
pression [10]. Several recent studies showed the efficacy
of exercise in the treatment of depression as an augmen-
tation for antidepressant treatment [11-13].
However, some problems elucidated in previous stud-
ies concerning the efficacy of exercise on depression re-
main to be clarified. Firstly, subjects attended a series of
exercise sessions delivered within a group format.Therefore, it is difficult to distinguish the effect of the
exercise itself from the effect of group dynamics. Sec-
ondly, the effect of exercise was measured mainly with
psychometric instruments, such as self-administered
testing (e.g., Beck Depression Inventory) or question-
naires by clinicians (e.g., Hamilton Rating Scale for De-
pression). To date, no objective measurements that
reflect the pathophysiological mechanisms underlying
depression have been used to evaluate the effectiveness
of exercise.
To elucidate the latter problem, we focused on
hypothalamic-pituitary-adrenocortical (HPA) axis dys-
function in depression, which is the most valid current
neurobiological theory for explaining the pathophysi-
ology of depression. The HPA axis consists of the inter-
actions among the hypothalamus, the pituitary gland,
and the adrenal cortex, and is a major part of the neuro-
endocrine system that controls reactions to stress [14].
The clinical manifestation of its dysfunction in depres-
sion includes basal hypercortisolemia [15], elevated cor-
tisol secretion in the dexamethasone suppression test
[16], and increased cortisol release in the combined
dexamethasone suppression-corticotropine releasing
hormone stimulation test [17,18].
Recently, the measurement of saliva free cortisol level
has made it possible to explore the involvement of dys-
regulation of the HPA axis in the pathophysiology of de-
pression [19]. Saliva free cortisol is a protein-unbound
cortisol that exerts bioactivity of the hormone, which is
well correlated with the serum cortisol level. Moreover,
the determination of the saliva free cortisol level is a
non-invasive method, which can avoid change in the
concentration by stimulation of blood sampling in cases
of serum cortisol determination [19].
For these reasons, by assessing the change in saliva
free cortisol level before and after exercise, we felt that
we would be able to objectively determine the efficacy of
exercise on depressive symptoms and to clarify the bio-
logical mechanisms underlying the effect of exercise.
In this paper, we examined the efficacy of a single ses-
sion of individual exercise on the depressive symptoms
of depressive patients by assessing the change in the sal-
iva free cortisol level.
To the best of our knowledge, this is the first report
that used the saliva free cortisol level for the measure-




Between July 2008 and July 2009, 39 outpatients at the
Department of Neuropsychiatry in the National Hospital
Organization Takasaki General Medical Center who met
the DSM-IV-TR criteria for major depressive disorder
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purpose and procedures were explained by the patient’s
psychiatrist. Exclusion criteria were comorbid condi-
tions, including substance abuse, current medical condi-
tions that might lead to global cognitive impairment or
cerebrovascular risk factors, pregnancy that might cause
alteration in adrenocortical activity, and specific medical
contraindications for exercise.
Of the 39 who met the inclusion criteria, 18 agreed to
participate.
Study protocol
The eighteen participants were invited to an exercise
session at our hospital. After one month, they were also
invited to a control session that involved sitting quietly.
If the participant had been given antidepressants before
entry, the dosage was fixed for the duration of the study.
At both sessions, we assessed the change in the saliva
free cortisol level of each participant and the change in
subjective depressive symptom scores before and after
the sessions in order to examine the effect of the exer-
cise on the participants’ depressive symptoms.
All participants provided written informed consent
after a full explanation of the study purpose and proce-
dures. This study was conducted in accordance with the
Declaration of Helsinki and was approved by the ethics
council of the National Hospital Organization Takasaki
General Medical Center.
Exercise session
The exercise that we chose was pedaling a bicycle erg-
ometer (Aerobike 2000U, COMBI, Japan) by oneself.
Before participants’ routine consultation, they were in-
vited to practice pedaling the bicycle ergometer for 15
minutes at the same time of day (between 13:00 and
14:00). The exercise load was unified with the Borg Rat-
ing of Perceived Exertion Scale (Borg RPE Scale), which
is very popular in health sciences for quantifying exer-
tion. It has been translated into many languages, includ-
ing Japanese [21]. The scale values range from 6
(exertion: very, very light) to 20 (very, very hard), which
denote heart rates ranging from 60-200 beats per mi-
nute. The participants were instructed to regulate their
speed of pedaling the bicycle ergometer within the range
from 11 (exertion: fairly light) to 13 (somewhat hard) on
the Borg RPE Scale. In addition, the participant’s heart
rate was recorded to show the actual exercise load that
was done and the change in autonomic nerve system
function related to the exercise.
To insure that the discomfort caused by the unfamiliar
environment would not affect the participant’s saliva free
cortisol level, the bicycle ergometer was set up in the
room next to the consulting room, and their doctor was
with the participant during the exercise session.Control session
Within one month after the exercise session, the partici-
pants were asked to attend a control session. Of the 18
participants, three did not participate in the control ses-
sion because they could not come to the hospital. Case 1
and 7 had reached complete remission and Case 8 had
changed hospitals. As a result, the data of fifteen partici-
pants was available.
Also, before the routine consultation the participants
were asked to sit quietly in a waiting room for 15 mi-
nutes. The control session took place at the same time
of day (13:00-14:00) as the exercise session in order to
exclude a change in the saliva free cortisol level based
on the circadian rhythm.
Assessment and outcome measures
Severity of depressive symptoms
Before the exercise session, the level of depressive se-
verity was assessed with the 17-item Hamilton Rating
Scale for Depression (HRSD-17) [22]. This is a widely
used semi-structured interview that covers a range of
affective, behavioral, and physical symptoms of de-
pression. The scores range from 0 to 52, with a score
of 0-7 considered to be within the normal range or
clinical remission, a score of 8-19 indicating mild se-
verity, and a score of 20 or higher indicating at least
moderate severity. An experienced psychiatrist, the at-
tending doctor of the participant, administered the
HRSD-17.
Health related quality of life
Before the exercise session, we examined psychosocial
disability by measuring the health related quality of life
(HRQOL) of each participant with the Medical Outcome
Study Short-Form 36-Item Health Survey (SF-36) [23].
SF-36 is based on multi-dimensional health concepts
and consists of the subscales of eight dimensions and
the two summary scales shown below that measure the
full range of health states. It has proved to be a useful
HRQOL survey for many patient populations, including
depressive patients [24-26]. We adopted version 2.0 of
the SF-36 Japanese edition (SF-36v2™), which has been
validated for the Japanese population [27-29]. SF-36v2™
uses norm-based scoring, so that we can calculate each
score compared to the national-norm of 50. A higher
score than 50 indicates better HRQOL than the national
standard.
The eight SF-36 subscales and two summary scales
are:
 Physical functioning (PF): physical ability to do daily
activities
 Physical role functioning (RP): physical ability to
fulfill a daily role, such as work or housework
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 Social functioning (SF): ability to socialize with
family and friends
 General health (GH): subjective assessment of
general health
 Vitality (VT): perceived physical energy
 Emotional role functioning (RE): ability to
emotionally fulfill daily roles
 Mental health (MH): feelings of depression and
nervousness, or relaxation and fun.
From the aggregation of these subscales, two distinct
higher-level summary scores are available.
 Physical component summary (PCS): general
physical health state
 Mental component summary (MCS): general mental
health stateParticipants’ preferences for physical exercise and their
physical activity habits
Before the exercise session, the participants’ prefer-
ences for physical exercise, their daily exercise habits,
and their reasons for exercising were asked via writ-
ten inquiries and interviews. The questions were a)
“Do you like exercise?” with answers “yes”, “no” or
“uncertain”, b) “What kind of exercise do you actually
do?” and c) “Why do you exercise?”.Saliva free cortisol level
A saliva sample was collected from each participant
three times during the exercise and control sessions:
just before the session, immediately after the session,
and 10 minutes later.
The reason for selecting 10 minutes after as the
end point of saliva sampling is that it took 10 mi-
nutes for the heart rate at the end of the exercise
period to return to the pre-exercise rate in our pre-
liminary examination (Data not shown). At each saliva
sampling, the participant was asked to bite a small
cotton roll for 90 seconds, after which the cotton roll,
including the participant’s saliva, was placed into a
container (Salivette™, SARSTEDT AG & Co.,
Germany) designed to be able to remove the saliva
from the cotton by centrifugation. During both ses-
sions, the participant was instructed to refrain from
gargling in order to prevent a change in the saliva
free cortisol level.
The container was centrifuged at 1,000 g for 2 minutes
and stored at -20°C until biochemical analysis. The saliva
free cortisol level was measured by radioimmunoassay at
the SRL Corporation (Tokyo, Japan) using a radio-
immunoassay kit with 125I, (GammaCoat™ Cortisol, Dia-
Sorin, Inc., Stillwater, MN). The saliva free cortisol level
detection range of this kit is 0.06–9990 μg/dL.Subjective depressive symptom score
To evaluate the change in subjective depressive symptoms
before and immediately after the exercise and control ses-
sions, eight depressive symptoms were self-rated.
Six of these symptoms, which we expected to be im-
proved by a single session of exercise and that were easy for
the participants to understand were excerpted from HRSD-
17, a widely used semi-structured interview for the diagno-
sis of the severity of depression that has proven validity as a
psychometric measure [22]. Moreover, it has been used as
the outcome measure for assessing the effect of exercise in
depressive patients [11-13]. The six symptoms we selected
are depressed mood, disability of concentration (retardation
is included in HRSD-17), agitation, anxiety, fatiguability (in-
cluded in the somatic symptoms of HRSD-17), and hypo-
chondriasis. In addition, we added two symptoms to the
subjective depressive symptom score for this study. Per-
ceived stress level and confidence about self-ability were
not included in HRSD-17, but were expected to be im-
proved by a single session of exercise.
Each symptom was scored on a four-point scale, ranging
from 0 to 3. A score of 0 represents the absence of that
subjective symptom, and the scores of 1, 2, and 3 indicate
mild, moderate, or severe symptom respectively, except for
confidence about self-ability. For this symptom, a higher
score represents the lower confidence; the score was re-
versed when calculating the total subjective depressive
symptom score.
Statistical analysis
All statistical analyses were performed using R version
2.9.0, a free software program for statistical computing [30].
The changes in the saliva free cortisol levels before, imme-
diately after, and 10 minutes after the exercise and control
sessions were evaluated with the Friedman-rank-sum-test.
The changes in the subjective depressive symptom scores
before and immediately after the sessions were evaluated
with the Wilcoxon-signed-rank-test. These tests were
adopted because the results of the Shapiro-Wilk test for sal-
iva free cortisol level and the subjective depressive symp-
tom scores before the exercise session suggested that these
two variables were non-parametric.
The correlation between the changes in saliva free cor-
tisol level and the changes in subjective depressive
symptom scores before and immediately after the ses-
sions were evaluated with the Spearman's-rank-correl-
ation-coefficient. The correlation between the pre-
exercise saliva free cortisol level and, HRSD-17 scores
and SF-36v2™ scores were evaluated likewise.
Results
Participant characteristics
Demographic and clinical characteristics of the eighteen
participants at entry to the study are shown in Table 1.
Table 1 Demographic and clinical characteristics of all eighteen participants
Case No. Age
(years)
















1 31 M 45 44 3 4 SULP (150) AMI (150) 14 −7.2 34.4
2 27 F 27 27 16 1 SER (150) 8 38.6 46.7
3 55 F 9 9 9 2 TRZ (75) MIA (10) 10 35.3 56.0
4 56 F 103 103 6 4 AMI (150) 14 20.2 26.8
5 28 F 14 14 14 0 SER (100) 14 36.6 39.4
6 37 M 20 20 20 1 SER (100) 13 5.1 39.3
7 61 F 105 105 6 3 SER (125) 6 49.6 56.9
8 38 M 62 62 3 0 AMI (150) 14 39.7 26.5
9 32 F 42 42 12 1 AMI (25) 8 18.9 47.3
10 44 F 316 316 14 6 SULP (100) 7 25.2 51.0
11 53 M 7 7 7 0 SER (75) 6 23.5 52.3
12 37 M 84 84 1.5 3 MIL (150) 22 28.2 25.3
13 56 M 10 5 6 0 PAROX (40) 9 NA NA
14 53 F 9 9 10 0 SER (75) 5 49.3 64.9
15 68 F 18 18 8 1 MIL (100) 3 51.5 64.3
16 61 F 204 144 11 1 MIL (50) 6 35.5 40.4
17 31 M 12 12 12 0 MIL (100) 8 48.4 39.4
18 58 F 12 12 12 0 AMI (100) 3 40.3 36.7
Mean 45.9 M = 7 61.1 57.4 9.5 1.5 9.4 31.7 44.0
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Each participant’s HRSD-17 sore is shown in Table 1.
Seven participants were in clinical remission (HRSD-
17≦7), ten suffered from mild depression (8≦HRSD-
17≦19), and one suffered from moderate depression
(HRSD-17≧20). All participants were taking therapeutic
doses of antidepressants for the purpose of acute phase
treatment, continuation, or maintenance treatment for
preventing recurrence.
However, the mean duration of illness was 61.1 ± 81.5
months, which indicated long-term depression. More-
over, as shown by the number of previous depressive ep-
isodes, not a few of them had repeated recurrence, even
though they were under long-term medication.
Furthermore, the participants’ mean total HRSD-17
score before the control session was 8.3 ± 6.8, a non sig-
nificant difference from the mean HRSD-17 score before
the exercise session (9.5 ± 4.9).
HRQOL
PCS and MCS scores are shown in Table 1. Moreover,
the mean SF-36v2™ eight subscale scores and two sum-
mary scale scores of all eighteen participants are shown
in Table 2.
All SF-36v2™ subscale scores and summary scale
scores were lower than the national-norm of 50. Espe-
cially, RP and RE scores, which indicate how a person
can fulfill daily roles like work and household chores,
physically and mentally, and scores of SF, which indicate
how a person socializes with family members, friends
and companions, were remarkably low. In addition, the
PCS score, which represents general physical health, was
lower than the MCS, which represents general mental
health.
Correlation between severity of depression and HRQOL
The SF-36v2™ subscale scores, except for PF and BP and
two summary scores, of all participants wereTable 2 The mean SF-36v2TM eight subscale scores and
two summary scale scores of all eighteen participants
SF-36 scales Mean score SD
Physical functioning (PF) 40.4 15.2
Physical role functioning (RP) 31.2 15.7
Bodily Pain (BP) 42.7 14.9
General health (GH) 41.5 10.8
Vitality (VT) 42.7 15.5
Social functioning (SF) 33.8 16.3
Emotional role functioning (RE) 32.1 16.2
Mental health (MH) 42.6 13.3
Physical component summary (PCS) 31.7 16.2
Mental component summary (MCS) 44.0 12.4significantly, negatively correlated with their total
HRSD-17 scores.
RP, MH and MCS scores were strongly correlated to total
HRSD-17 scores, with correlation coefficients of -0.79,
-0.78, and -0.72 (p < 0.01), respectively. RE, VT, SF, PCS
and GH were moderately correlated to total HRSD-17
scores, with correlation coefficients of -0.68, -0.64, -0.58,
-0.55 and -0.52 (p < 0.05), respectively. The severity of de-
pressive symptoms corresponded with the decline in
HRQOL scores.Participants’ preferences for physical exercise and their
physical activity habits
Of the 18 participants, 17 reported to like exercise and ac-
tually did some kind of routine exercise. The exercises that
most of the participants participated in were taking walks
near their house (12 participants) and cycling (2 partici-
pants). Their reasons for exercising were as follows, main-
taining or promoting health, changing their mood, losing
weight, prevention of aging, and getting out of their house.
Some participants exercised because of their family’s
recommendation.
Our participants performed exercises as a favorite pas-
time, but they also exercised in order to improve their
state of health and quality of life.
Some participants realized an improvement in their
mood during and after exercise, but some answered that
they still could not escape from unnecessary thoughts
during exercise.Smoking status
None of the participants were habitual smokers, and
none smoked during the study.Results of the sessions
Exercise load
During the exercise session, the mean Borg RPE Scale
score was 11.7 ± 1.1. Thus, the exertion during the exer-
cise session was fairly light and within the range that the
participants were instructed to perform (Borg RPE Scale:
11-13).
The mean heart rates before, immediately after, and 10
minutes after the exercise session were 83.4 ± 18.6,
112.3 ± 9.4, and 87.5 ± 17.1 beats per minute, respect-
ively. Importantly, the heart rate returned to the pre-
exercise value within ten minutes. Also, the value just
after the exercise session corresponded with the Borg
RPE Scale score during the exercise. This shows that the
participants’ autonomic nerve function as monitored by
their heart rates had returned to the pre-exercise state
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level and HRSD-17, SF-36v2TM scores
The pre-exercise saliva free cortisol level was signifi-
cantly, positively correlated with the total HRSD-17
scores (r = 0.54, p < 0.05). In addition, the pre-exercise
saliva free cortisol level was negatively correlated with
two SF-36v2™ subscale scores, RP and VT, with correl-
ation coefficients of -0.52 and -0.50 (p < 0.05). The pre-
exercise saliva free cortisol level corresponded to the
severity of depressive symptoms and a decline in the





Figure 2 Boxplot of time course change in the saliva free
cortisol levels of 15 participants during the control session.
Each box includes 50% of the cases (between percentils 25 and 75).
The black line inside represents the median and the whiskers show
extreme cases of individual variables.Saliva free cortisol level change
Figure 1 shows the change in the saliva free cortisol level
of all eighteen participants during the exercise session.
The saliva free cortisol level was decreased significantly
before, immediately after, and ten minutes after the exer-
cise session (Friedman rank sum test: χ2 = 11.303, df =2,
p < 0.001). In addition, there was a significant difference
in the saliva free cortisol levels before and 10 minutes
after the exercise (Wilcoxon signed rank test: p < 0.05).
The changes in saliva free cortisol levels in the control
session are shown in Figure 2. In contrast with the exer-
cise session, the overall saliva free cortisol levels did not
change during the session. Also, there were no signifi-
cant differences in the saliva free cortisol level in com-
















Figure 1 Boxplot of time course change in the saliva free
cortisol levels of the 18 participants during the exercise
session. Each box includes 50% of the cases (between percentils 25
and 75). The black line inside represents the median and the
whiskers show extreme cases of individual variables. *p < 0.05 as
compared to value before the exercise.Change in subjective depressive symptom scores
The changes in subjective depressive symptom scores
before and after both the exercise and control sessions
are shown in Figure 3 and Figure 4. Scores shown in the
figures are the total of the eight subjective depressive
symptom scores as perceived by the participants. The
subjective depressive symptom scores were significantly
decreased in both sessions (p < 0.01).
The relationship between the changes in the saliva free
cortisol level and the changes in the subjective depressive
symptom scores
As shown in Figure 5, the changes in the saliva free cor-
tisol levels of all eighteen participants pre and immedi-
ately after the exercise session (i.e. scores of pre-exercise
session minus scores immediately after the exercise ses-
sion) were significantly correlated to the changes in the
subjective depressive symptom scores (r = 0.50, p < 0.05).
However, in the control session, no significant correl-
ation was shown between the changes in saliva free cor-
tisol levels and the changes in subjective depressive
symptom scores.
Discussion
The relationship between our participants’ characteristics
and the possibility of exercise as an augmentation
therapy for depression
Almost all of our participants were in remission or in
mild depressive state treated with antidepressants. How-
ever, their duration of illness was long and their







Figure 5 Correlation between the changes in the saliva free
cortisol levels of the 18 participants before and immediately
after the exercise session (scores of the pre-exercise session




















Before exercise  After exercise 
Figure 3 Box plot of change in the subjective depressive
symptom scores of the 18 participants before and after the
exercise session. Each box includes 50% of the cases (between
percentils 25 and 75). The black line inside represents the median
and the whiskers show extreme cases of individual variables.




















Before sitting       After sitting
Figure 4 Boxplot of change in the subjective depressive
symptom scores of 15 participants before and after the control
session. Each box includes 50% of the cases (between percentils 25
and 75). The black line inside represents the median and the
whiskers show extreme cases of individual variables. *p < 0.01 as
compared to the value before the control session.
Ida et al. BioPsychoSocial Medicine 2013, 7:18 Page 8 of 11
http://www.bpsmedicine.com/content/7/1/18HRQOL, which was directly correlated with the severity
of depression, remained lower than the national-norm.
HRQOL, which is a reflection of the psychosocial dis-
abilities of depressive patients, is a useful outcome meas-
ure for depression and an important target for
improvement through treatment [31]. In line with our
findings, previous reports demonstrated that depression
has a profound impact on patient’s HRQOL [32,33].
Furthermore, recent studies exploring the HRQOL of
depressive patients disclosed disturbances in the physical
as well as the mental aspects of HRQOL [7,34]. For our
participants’ HRQOL, the physical aspects, RP, SF, and
PCS were remarkably low.
This fact deserves attention in considering the efficacy
of exercise on depressive symptoms because it goes
without saying that exercise acts on physical aspects of
individuals. Moreover, our participants themselves chose
to exercises daily in order to improve their health and
quality of life.
For these reasons, exercise would naturally be accept-
able for depressive patients and, moreover, the exercise
is a potentially effective augmentation for antidepressant
therapy, improving HRQOL by directly acting on phys-
ical ability, which is disturbed in depressive patients.The relationship between the efficacy of exercise and the
change in saliva free cortisol level of depressive patients
As mentioned previously, the saliva free cortisol level is
a biological indicator that reflects HPA axis dysfunction
involved in the pathophysiology of depression. In fact, in
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cise session corresponded with the severity of depression
and decline in the physical aspects of HRQOL (RP and
VT). By adopting this indicator as the measurement of
the effectiveness of physical exercise on depressive
symptoms, we feel that it is possible to objectively exam-
ine the effect of exercise and, moreover, to explore
whether or not exercise influences the HPA axis func-
tion of depressive patients.
The most important finding in our study is that the
saliva free cortisol level is significantly decreased by a
single session of individual exercise that does not include
group dynamics. Moreover, the decrease in the saliva
free cortisol level was correlated with a decrease in the
subjective depressive symptom scores. This correlation
was statistically significant.
On the other hand, although subjective depressive
symptom scores improved in the control session, the sal-
iva free cortisol level did not change. Our data show that
the efficacy of physical exercise itself on depressive
symptoms is not only a subjective impression, but an ob-
jective fact, as shown by the change in the saliva free
cortisol level.
To our best knowledge, this is the first paper to clarify
the relationship between the efficacy of physical exercise
on depression and the change in saliva free cortical level,
reflecting the HPA axis function disturbance of depres-
sive patients. The following facts support these findings.
To date, there are only two studies comparing cortisol
response to physical exercise by depressive patients with
that of healthy controls. Kiive et al. [35] reported no dif-
ference in serum cortisol response to intensive physical
exercise by a group with depression and healthy con-
trols. Moreover, Krogh et al. [36] observed more blunt
cortisol response to exercise in depressed participants
than in healthy controls. In previous studies, physical ex-
ercise was adopted as a stressor, not as a treatment.
Moreover, serum, not saliva free cortisol level was mea-
sured. Thus, there have been no reports concerning the
relationship between the therapeutic effect of physical
exercise and the change in saliva free cortisol level.
To what extent do our present findings explain the in-
fluence of exercise on HPA axis function? In pharmaco-
therapy with antidepressants, numerous researchers
have used the saliva free cortisol level to examine the as-
sociation between their anti-depressive effect and the in-
fluence on the HPA axis function of depressive patients.
These studies have proven that several antidepressants,
including TCA [37], SSRI [38], SNRI and NaSSa [39] im-
proved depressive symptoms, with a reduction of the sal-
iva free cortisol level. These reports suggested that the
efficacy of antidepressants is exerted via the recovery of
the HPA axis dysfunction involved in the pathophysi-
ology underlying depression.The present results show that the anti-depressive effi-
cacy of physical exercise itself has a similar mechanism
to that of antidepressants, because exercise also induces
a reduction of the saliva free cortisol level. However, to
confirm this, further examination will be necessary to
prove that the reduction of saliva free cortisol level of
drug-free depressive patients is induced by exercise. Fur-
thermore, if healthy subjects show a significantly lower
basal saliva free cortisol level and more blunt response
to physical exercise as compared with depressive pa-
tients, we could more strongly confirm the hypothesis.
To that end, further investigation is needed.Limitations
Our present study has several limitations.
Firstly, the sample size was small and all of the partici-
pants were medicated during the study period. Further
study with a larger number of participants and that in-
cludes drug-free patients will be necessary.
Secondly, the subjective depressive symptom scores,
which evaluate the change in subjective depressive
symptoms during intervention, was not sufficiently vali-
dated and must be confirmed in a future study with a
larger sample size.
Thirdly, the interventions were not conducted with a
counterbalanced design to control for order effect.
Fourthly, we did not clarify the effect of repetitive ex-
ercise. Therefore, we did not examine the long-term ef-
fect of physical exercise on the change of saliva free
cortisol level.
We must overcome the issues above in future study to
establish that physical exercise is useful for augmenting
antidepressant therapy for depressive patients, and to
clarify the anti-depressive effect of physical exercise by
assessing the change in saliva free cortisol level.Conclusion
The value of assessing the effect of exercise by the saliva
free cortisol level of depressive patients
In this clinical study, we documented for the first time a
decrease in the saliva free cortisol level due to exercise
itself, and that the decrease was accompanied by an im-
provement in the subjective depressive symptoms of de-
pressive patients. Although the number of participants
was small, the efficacy of a single session of independent
exercise by depressive patients was objectively con-
firmed. Moreover, exercise was shown to be a naturally
acceptable intervention for depressive patients, as shown
by our participants’ reported preferences for exercise
and their daily exercise habits.
Our results suggest the utility of the saliva free cortisol
level for assessing the effect of exercise by depressive pa-
tients who suffer from bio-psycho-social disability.
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